Open-market purchases and sales reported on SEC Forms 4 and 5, with each filing and its footnotes.
Since Nov 17, 2025
Transactions
14
Purchases
6
Sales
8
Purchase value
$1.49M
Sale value
$58.98M
Values are shares multiplied by reported price when both were supplied, each trade counted once however many filers reported it.
Tang Capital Management LLC10% owner
Tang Kevin10% owner
4
Filed Jul 20, 2026Period of report Jul 16, 20260001178579-26-000016
Transaction
Security
Shares
Price
ValueValue (shares × price)
Held after
Ownership
PurchaseJul 17, 2026
Common StockF3F2
50,945
$3.52
$179.33K
7,080,945
IndirectSee Footnote
PurchaseJul 16, 2026
Common StockF1F2
116,671
$3.56
$415.35K
7,030,000
IndirectSee Footnote
Filing footnotes · 3
F1The prices reported are weighted-average prices. These shares were purchased in multiple transactions at prices ranging from $3.50 to $3.60. The Reporting Persons undertake to provide the Issuer, any security holder of the Issuer or the SEC staff, upon request, all information regarding the number of shares purchased at each price within the ranges set forth in Footnotes 1 and 3.
F2Tang Capital Partners, LP ("TCP") beneficially owns 1,668,554 shares, Tang Capital Partners International, LP ("TCPI") beneficially owns 2,212,803 shares, Tang Capital Partners III, Inc. ("TCP III") beneficially owns 1,668,539 shares, and Tang Capital Partners IV, Inc. ("TCP IV") beneficially owns 1,531,049 shares. Kevin Tang is the sole manager of Tang Capital Management, LLC, which is the general partner of TCP and TCPI. Kevin Tang is the sole director and Chief Executive Officer of TCP III and TCP IV, which are indirectly wholly owned by TCP. Mr. Tang has a pecuniary interest in the shares beneficially held by TCP, TCPI, TCP III and TCP IV.
F3These shares were purchased in multiple transactions at prices ranging from $3.46 to $3.55.
Filed Jul 15, 2026Period of report Jul 13, 20260001178579-26-000014
Transaction
Security
Shares
Price
ValueValue (shares × price)
Held after
Ownership
PurchaseJul 15, 2026
Common StockF5F2
107,377
$3.56
$382.26K
6,913,329
IndirectSee Footnote
PurchaseJul 14, 2026
Common StockF3F2
53,651
$3.56
$191.00K
6,730,000
IndirectSee Footnote
PurchaseJul 14, 2026
Common StockF4F2
75,952
$3.58
$271.91K
6,805,952
IndirectSee Footnote
PurchaseJul 13, 2026
Common StockF1F2
12,966
$3.54
$45.90K
6,676,349
IndirectSee Footnote
Filing footnotes · 5
F1The prices reported are weighted-average prices. These shares were purchased in multiple transactions at prices ranging from $3.54 to $3.55. The Reporting Persons undertake to provide the Issuer, any security holder of the Issuer or the SEC staff, upon request, all information regarding the number of shares purchased at each price within the ranges set forth in Footnotes 1 and 3 through 5.
F2Tang Capital Partners, LP ("TCP") beneficially owns 1,630,142 shares, Tang Capital Partners International, LP ("TCPI") beneficially owns 2,160,423 shares, Tang Capital Partners III, Inc. ("TCP III") beneficially owns 1,630,127 shares, and Tang Capital Partners IV, Inc. ("TCP IV") beneficially owns 1,492,637 shares. Kevin Tang is the sole manager of Tang Capital Management, LLC, which is the general partner of TCP and TCPI. Kevin Tang is the sole director and Chief Executive Officer of TCP III and TCP IV, which are indirectly wholly owned by TCP. Mr. Tang has a pecuniary interest in the shares beneficially held by TCP, TCPI, TCP III and TCP IV.
F3These shares were purchased in multiple transactions at prices ranging from $3.54 to $3.60.
F4These shares were purchased in multiple transactions at prices ranging from $3.53 to $3.60.
F5These shares were purchased in multiple transactions at prices ranging from $3.50 to $3.60.
Filed Jun 30, 2026Period of report Jun 26, 20260001193125-26-290622
Transaction
Security
Shares
Price
ValueValue (shares × price)
Held after
Ownership
SaleJun 26, 2026
Common StockF1F2
18,000
$3.6452
$65.61K
10,927
Direct
Filing footnotes · 2
F1The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 27, 2026.
F2The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.555 to $3.82, inclusive. The reporting person undertakes to provide to Fulcrum Therapeutics, Inc., any security holder of Fulcrum Therapeutics, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4.
Filed Feb 4, 2026Period of report Feb 2, 20260001193125-26-037573
Transaction
Security
Shares
Price
ValueValue (shares × price)
Held after
Ownership
SaleFeb 2, 2026
Common StockF1F2
15,000
$10.7238
$160.86K
454,864
Direct
Filing footnotes · 2
F1The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 1, 2025.
F2The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.48 to $11.10, inclusive. The reporting person undertakes to provide to Fulcrum Therapeutics, Inc., any security holder of Fulcrum Therapeutics, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4.
Filed Feb 4, 2026Period of report Jan 2, 20260001193125-26-037606
Transaction
Security
Shares
Price
ValueValue (shares × price)
Held after
Ownership
SaleJan 2, 2026
Common StockF1F2
15,000
$10.8726
$163.09K
469,864
Direct
Filing footnotes · 2
F1The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 1, 2025.
F2The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.60 to $11.33, inclusive. The reporting person undertakes to provide to Fulcrum Therapeutics, Inc., any security holder of Fulcrum Therapeutics, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4. This Form 4/A corrects the weighted average price indicated in the Form 4 submitted on January 6, 2026 from $11.8726 to $10.8726.
Filed Dec 10, 2025Period of report Dec 8, 20250001231919-25-000596
Transaction
Security
Shares
Price
ValueValue (shares × price)
Held after
Ownership
SaleDec 8, 2025
Common StockF1F2F3
1,377,020
$13.33
$18.36M
8,852,079
IndirectSee footnotes
SaleDec 8, 2025
Common StockF4F2F3
2,706,397
$14.28
$38.65M
6,145,682
IndirectSee footnotes
SaleDec 8, 2025
Common StockF5F2F3
91,722
$14.98
$1.37M
6,053,960
IndirectSee footnotes
Filing footnotes · 5
F1The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.81 to $13.8099 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F2RA Capital Management, L.P. (the "Adviser") is the investment manager for the Fund. The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. Each of the Adviser, the Adviser GP, the Fund, Dr. Kolchinsky and Mr. Shah disclaims beneficial ownership of any of the reported securities, except to the extent of its or his respective pecuniary interest therein.
F3Held directly by the Fund.
F4The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.81 to $14.805 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F5The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.81 to $15.39 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Filed Nov 21, 2025Period of report Nov 19, 20250001193125-25-291392
Transaction
Security
Shares
Price
ValueValue (shares × price)
Held after
Ownership
SaleNov 19, 2025
Common StockF1F2
15,000
$11.033
$165.50K
484,864
Direct
Filing footnotes · 2
F1The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 1, 2025.
F2The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.50 to $11.18, inclusive. The reporting person undertakes to provide to Fulcrum Therapeutics, Inc., any security holder of Fulcrum Therapeutics, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4.
P and S transaction codes only. Grants, gifts, option exercises, tax withholding, and Form 144 notices are not counted as purchases or sales. A row whose filed price fails a plausibility check, or that is not common stock, is listed but left out of the values; a trade reported by several filers is counted once.